New Challenges in Infertility Treatment

Saturday, October 1, 2022, 9:20 AM - Tuesday, September 30, 2025, 12:00 AM


AMA PRA Category 1 Credits™ (25.00 hours), Non-Physician Attendance (25.00 hours)

Management of infertility with assisted reproductive technology (ART) has changed substantially over the past ten to fifteen years due to the application of new technological advancements in this field and a better understanding of reproductive pathophysiology.

Today, ART can be used not only in patients experiencing infertility but also in those who experience recurrent miscarriage, have chronic viral infections, or have cancer. ART can reduce the time it takes to achieve pregnancy, reduce the risk of viral infection transmission, and allow for fertility preservation (FP).

In the same way, knowledge from other medical fields, such as genetics and immunology, and the use of techniques such as next-generation sequencing (NGS), which studies microbiome or endometrial receptivity, facilitate a multidisciplinary approach that can help improve reproductive outcomes.

Clinicians who treat patients with infertility can face several challenges in selecting the appropriate treatment option for their patients, including successfully addressing implantation failure or applying ART to other special situations where it could contribute to fertility preservation or risk management.

This education program is designed to offer a multidisciplinary approach to ART to maximize clinical outcomes in this field.

1. Assess the possible causes of recurrent miscarriage.
2. Discuss the treatment approach related to immunology to improve reproductive rates.
3. Choose the best treatment option in recurrent miscarriage.
4. Discuss about the causes producing implantation failure.
5. Explain how chronic viral infections such as HIV and hepatitis can impact reproduction capacity.
6. Analyze most relevant issues concerning COVID-19 and Assisted Reproduction to improve the safety of the techniques.
7. Choose the most adequate fertility preservation protocol for each patient.
8. List genetic causes of infertility.
9. Choose the best protocol treatment based on the genetic cause of infertility to improve reproductive outcomes.
10. Explain how ovarian rejuvenation techniques work.
11. Apply an adequate protocol for endometrial receptivity assessment.
12. Analyze immune system role in endometrial receptivity and reproductive outcomes.

To register for this activity, click here. By clicking on this link, you will be taken to the IVIRMA Global Education website.

Have questions or need learner support? Send an email to [email protected].

In support of improving patient care, this activity has been planned and implemented by Thomas Jefferson University and IVIRMA Global Education. Thomas Jefferson University is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians: This educational activity is designated for a maximum of 25.00 AMA PRA Category 1 Credits ^TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals: This educational activity is designated for 25.00 AMA PRA Category 1 Credit ^TM. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Jefferson Release Policy

Jefferson may record/livestream/photograph this educational activity. These images/recordings, along with your name, may be used in Jefferson publications or on the Jefferson website. If you verbally submit any questions for Q&A sessions, you are agreeing to be recorded and to have that recording available in enduring materials. Once photographed, filmed, recorded, or videotaped, you waive the right of inspection or approval to which such images/recordings may be put and Jefferson has the right to use, publish, reproduce, modify, adapt, and distribute at any time in any manner or medium.

Jefferson HIPAA Policy

As an attendee of this educational activity hosted by Thomas Jefferson University, Jefferson University Physicians, and Thomas Jefferson University Hospitals, Inc. (collectively 'Jefferson'), you may gain access to certain proprietary information ('Confidential Information'), including Protected Health Information ('PHI').

By participating in this educational activity, you agree to maintain the confidentiality of all Confidential Information, including all PHI, obtained from any source. You also agree to take all necessary steps to protect such Confidential Information and shall not directly or indirectly disclose or use it in any manner or for any reason, other than as necessary to complete the educational activity. Further, you agree not to take photographs, record in any manner or otherwise reproduce any such Confidential Information. You understand that any unauthorized use or disclosure of Confidential Information may result in possible legal action against you by Jefferson whose confidentiality is breached.

Planning Committee
No member of the planning committee have any relevant financial relationships to disclose.
William Schlaff, MD
Juan Giles, MD, PhD

Faculty
No member of faculty have any relevant financial relationships to disclose.

Mitigation of Relevant Financial Relationships

Thomas Jefferson University adheres to the Standards for Integrity and Independence in Accredited Continuing Education and the policies that supplement the Standards.

All planners, faculty, and others in control of educational content are required to disclose any relevant financial relationships with ACCME defined ineligible companies within the past 24 months. Any conflicts of interests have been mitigated prior to this educational activity. Such disclosures will be available prior to the start of the activity. Jefferson conflict of interest mitigation process may result in changes to the program agenda.

Off-Label/Investigational Use
All faculty/presenters/authors at Thomas Jefferson University sponsored events are required to disclose whether or not their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Product(s) is/are not included in the labeling approved by the U.S. FDA for the treatment of disease(s).

Content Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or Thomas Jefferson University.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

 

This educational activity received no commercial or in-kind support.